Negative perception in those at highest risk - Potential challenges in colorectal cancer screening in an urban Asian population

Asian Pacific Journal of Cancer Prevention

Volumn 11, Issue 3, 2010, Pages 815-822

  Hilmi, Ida ^a   Hartono, Juanda Leo ^a   Goh, K L ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Colorectal cancer screening; Ethnicity; Malaysia

Indexed keywords

EID: 78650688875     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Aubry C, Spyckerelle Y, et al (1989). Public knowledge and attitude towards colorectal cancer. Gastroenterol Clin Biol, 13, 596-601.
2. Chew, M. H., N. Suzanah, et al (2009). Colorectal cancer mass screening event utilising quantitative faecal occult blood test. Singapore Med J, 50, 348-53.
3. Fujita M. Nakano Y, et al (1986). Mass screening for colorectal cancer by testing fecal occult blood. Cancer, 57, 2241-5.
4. Glanz K, L. F., Rimer BK (2002). Health Behavior and Health Education.
5. Goh KL, Quek KF, et al (2005). Colorectal cancer in Asians: a demographic and anatomic survey in Malaysian patients undergoing colonoscopy. Aliment Pharmacol Ther, 22, 859-64.
6. Hakama M, Coleman MP, et al (2008). Cancer screening: evidence and practice in Europe 2008. Eur J Cancer, 44, 1404-3.
7. Heresbach D, Manfredi S, et al (2006). Review in depth and meta-analysis of controlled trials on colorectal cancer screening by faecal occult blood test. Eur J Gastroenterol Hepatol, 18, 427-33.
8. Hill MJ, Morson BC, et al (1978). Aetiology of adenomacarcinoma sequence in large bowel. Lancet, 1, 245-47.
9. Hou SI (2005). Factors associated with intentions for colorectal cancer screenings in a Chinese sample. Psychol Rep, 96, 159-62.
10. Janda M, Stanton WR, et al (2003). Knowledge, attitude and intentions related to colorectal cancer screening using faecal occult blood tests in a rural Australian population. Asia Pac J Public Health, 15, 50-6.
11. Janz NK, Wren PA, et al (2003). Colorectal cancer screening attitudes and behavior: a population-based study. Prev Med, 37, 627-34.
12. Keighley MR, O'Morain C, et al (2004). Public awareness of risk factors and screening for colorectal cancer in Europe. Eur J Cancer Prev, 13, 257-62.
13. Krishnaswamy S, K. Subramaniam, et al (2009). Factors contributing to utilization of health care services in Malaysia: a population-based study. Asia Pac J Public Health, 21, 442-50.
14. Lambert, R., C. Sauvaget, et al. (2009). Mass screening for colorectal cancer is not justified in most developing countries. Int J Cancer, 125, 253-6.
15. Lee KJ, Inoue M, et al (2007). Colorectal cancer screening using fecal occult blood test and subsequent risk of colorectal cancer: a prospective cohort study in Japan. Cancer Detect Prev, 31, 3-11.
16. Leung, W. K., K. Y. Ho, et al. (2006). Colorectal neoplasia in Asia: a multicenter colonoscopy survey in symptomatic patients.Gastrointest Endosc, 64, 751-9.
17. Lim C, S. Rampal, et al Cancer Incidence in Peninsular Malaysia 2003-2005.
18. McCaffery K, Wardle J, et al (2003). Knowledge, attitudes, and behavioral intentions in relation to the early detection of colorectal cancer in the United Kingdom. Prev Med, 36, 525-35.
19. Nichols C. Holt CL, et al (2009). Physician knowledge, perceptions of barriers, and patient colorectal cancer screening practices. Am J Med Qual, 24, 116-22.
20. Qureshi, A., M. Raj, et al. Screening for Colorectal Cancer in Malaysia Consensus/Clinical Practice Guidelines.
21. Steele, R. J., P. L. McClements, et al. (2009). Results from the first three rounds of the Scottish demonstration pilot of FOBT screening for colorectal cancer. Gut, 58, 530-5.
22. Sung J (2007). Colorectal cancer screening: its time for action in Asia.Cancer Detect Prev, 31, 1-2.
23. Sung JJ, Choi SY, et al (2008). Obstacles to colorectal cancer screening in Chinese: a study based on the health belief model. Am J Gastroenterol, 103, 974-81.
24. Sung JJ, Lau JY, et al (2005). Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol, 6, 871-6.
25. Guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst, 92, 205-16.
26. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al (2005). First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol, 23, 1178-84.
27. Weinshilboum R (2003). Inheritance and drug response. N Engl J Med, 348, 529-37.